Who is sponsoring NCT03720366?

NCT03720366 is sponsored by Celgene.

What condition does NCT03720366 study?

NCT03720366 studies Leukemia, Myeloid, Acute.

What drugs are being tested in NCT03720366?

Interventions: enasidenib, Arm 1 probes, Arm 2 Probes, Arm 3 probes.

What is the status of NCT03720366?

NCT03720366 is currently COMPLETED.

Last reviewed 2024-02-28 · How we verify

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

NCT03720366 PHASE1 COMPLETED

This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the probe compounds. (Part 1), followed by treatment continuation up to 28 months (Part 2). Each arm utilizes different probe compounds; enrolls a separate cohort of approximately 14 subjects; and consists of 2 parts - investigation of the PK effects of enasidenib on the respective probe compound(s) (Part 1), followed by an enasidenib treatment extension (Part 2).

Details

Lead sponsor	Celgene
Phase	PHASE1
Status	COMPLETED
Enrolment	40
Start date	Thu Oct 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Leukemia, Myeloid, Acute

Interventions

enasidenib
Arm 1 probes
Arm 2 Probes
Arm 3 probes

Countries

South Korea, Australia